Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

ENLV

Enlivex Therapeutics Ltd

Feb 12 • 04:00PM ET

1.10

-0.04 -3.51 %

Healthcare • Biotechnology • Israel • NASD

Peers: CRSP NTLA IOVA FATE BLUE EDIT ALLO SGMO KPTI ADAP

| Held by: QQQS

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.53	Insider Own	0.46%	Shs Outstand	237.38M	Perf Week	-5.17%
Market Cap	261.11M	Forward P/E	-	EPS next Y	-0.32	Insider Trans	0.00%	Shs Float	236.28M	Perf Month	24.35%
Enterprise Value	243.49M	PEG	-	EPS next Q	-0.09	Inst Own	0.34%	Short Float	0.22%	Perf Quarter	5.77%
Income	-12.70M	P/S	-	EPS this Y	39.01%	Inst Trans	-1.79%	Short Ratio	0.13	Perf Half Y	-29.49%
Sales	0.00M	P/B	1.53	EPS next Y	18.99%	ROA	-50.07%	Short Interest	0.53M	Perf YTD	56.43%
Book/sh	0.72	P/C	14.25	EPS next 5Y	-6.39%	ROE	-57.64%	52W High	2.10 -47.62%	Perf Year	4.76%
Cash/sh	0.08	P/FCF	-	EPS past 3/5Y	3.33% 7.57%	ROIC	-70.93%	52W Low	0.66 66.67%	Perf 3Y	-74.71%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	5.66% 8.22%	Perf 5Y	-94.50%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	46.09%	Oper. Margin	-	ATR (14)	0.08	Perf 10Y	-99.08%
Dividend Ex-Date	-	Quick Ratio	6.43	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	55.85	Recom	2.00
Dividend Gr. 3/5Y	- -	Current Ratio	6.43	EPS Q/Q	25.02%	SMA20	1.74%	Beta	1.57	Target Price	13.00
Payout	-	Debt/Eq	0.04	Sales Q/Q	-	SMA50	14.04%	Rel Volume	0.07	Prev Close	1.14
Employees	36	LT Debt/Eq	0.02	Earnings	Dec 01	SMA200	2.94%	Avg Volume	4.05M	Price	1.10
IPO	Jul 31, 2014	Option/Short	Yes / No	EPS/Sales Surpr.	11.36% -	Trades		Volume	265,237	Change	-3.51%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-02-21	Reiterated	H.C. Wainwright	Buy	$22 → $33

Feb-11-26 08:11AM	Enlivex Therapeutics announces new listing of RAIN token on Kraken (TipRanks)
Feb-10-26 08:00AM	Enlivex Treasury Portfolio Update: New Listing of the RAIN Token on Kraken, the Second-Largest U.S. Cryptocurrency Exchange (GlobeNewswire)
Jan-26-26 08:00AM	Enlivex Treasury Portfolio Update: Listing of the RAIN Token on WhiteBIT, a Leading Cryptocurrency Exchange (GlobeNewswire) +8.33%
Jan-23-26 08:00AM	Enlivex Therapeutics Shares to Trade Exclusively on Nasdaq (GlobeNewswire)
Jan-14-26 11:46AM	Analyst Sees Massive Upside For Penny Stock Enlivex After RAIN Token Gains Momentum (Benzinga) +9.26%
08:00AM	Loading…
Jan-07-26 08:00AM	Enlivex Treasury Portfolio Update: Listing of the RAIN Token on KuCoin, a Leading Cryptocurrency Exchange (GlobeNewswire)
Dec-04-25 08:00AM	Enlivex Management to Host Fireside Chat on December 11 to Discuss RAIN Token Strategy and Allocetra Clinical Development (GlobeNewswire) +6.42%
Nov-26-25 08:00AM	Enlivex Announces Closing of Previously Announced $212,000,000 Private Placement (GlobeNewswire) -8.16%
Nov-25-25 12:14PM	Nasdaq biotech firm bets $212m on new Arbitrum-based prediction market (DLNews)
Nov-24-25 04:51PM	Enlivex Unveils $212M Rain Token DAT Strategy as RAIN Surges Over 120% (Coinspeaker) +13.74%
10:00AM	Enlivex Appoints former Italy Prime Minister Matteo Renzi to Board of Directors (PR Newswire)
08:00AM	Microcap Biotech Firm Raises $212M for Prediction Market Token Treasury Strategy (CoinDesk)
07:55AM	Enlivex Announces $212,000,000 Private Placement to Initiate World's First Prediction Markets Digital Asset Treasury Strategy, via RAIN token Accumulation, and the Appointment of Matteo Renzi, Former Prime Minister of Italy, to its Board (GlobeNewswire)
07:46AM	EXCLUSIVE: Enlivex Raises Over $200 Million To Launch First Public Company Prediction Markets Play (Benzinga)
06:40AM	Enlivex Announces Positive 6-Month Topline Data -Demonstrating Durable and Persistent Pain Reduction and Improved Function in Primary Age-Related Patients with Moderate to Severe Knee Osteoarthritis (GlobeNewswire)
08:15AM	Loading…
Oct-28-25 08:15AM	Enlivex Therapeutics to Present Phase IIa 3-month Data of Allocetra in Patients with Moderate-to-Severe Knee Osteoarthritis at the ACR Convergence 2025 (GlobeNewswire)
Sep-29-25 08:15AM	D. Boral Capital to Host KOL Webinar With World Leading Experts Featuring Insights & Breakthroughs from Enlivex's Knee Osteoarthritis Program (GlobeNewswire)
Sep-11-25 08:00AM	Enlivex CEO Issues Letter to Shareholders Outlining Strategic Roadmap Following Positive Phase IIa Allocetra Results (GlobeNewswire) +5.42%
Sep-09-25 08:00AM	Enlivex Announces Issuance of New Patent Application Covering the Use of Allocetra in Patients with Osteoarthritis (GlobeNewswire)
Aug-19-25 07:53AM	Enlivex advances lead cell therapy to Phase IIb in osteoarthritis (Clinical Trials Arena) -16.00%
Aug-18-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) -31.32%
07:45AM	Enlivex Announces Positive Topline Data From Multi-Country, Randomized, Controlled, Phase I/II Trial Evaluating Allocetra in Patients With Moderate-To-Severe Knee Osteoarthritis (GlobeNewswire)
Aug-14-25 08:30AM	Enlivex to Present 3-Month Topline Data from Phase IIa Moderate/Severe Knee Osteoarthritis Trial on August 18 Webinar (GlobeNewswire) +14.10%
Jul-28-25 08:30AM	Enlivex Reaffirms August 18, 2025 As Target Date For Announcement of Phase II Topline Data (GlobeNewswire) +12.30%
Jun-10-25 08:30AM	Enlivex Therapeutics to Present Clinical Data of Allocetra in Osteoarthritis at EULAR 25 European Congress of Rheumatology (GlobeNewswire)
May-20-25 08:00AM	Enlivex Selected to Present at Israeli BioMed 2025 Conference (GlobeNewswire)
Apr-23-25 08:30AM	Enlivex Therapeutics to Showcase Allocetra's Potential in Osteoarthritis at OARSI 2025 World Congress (GlobeNewswire)
Apr-22-25 06:17AM	Enlivex enrols all patients in Phase II stage of knee osteoarthritis trial (Clinical Trials Arena)
Apr-21-25 08:30AM	Enlivex Announces Completion of Enrollment In The Phase II stage Of Its Phase I/II Trial Evaluating Allocetra In Patients With Moderate To Severe Knee Osteoarthritis (GlobeNewswire)
Apr-03-25 08:00AM	Enlivex Announces the Dosing of the First Patient in a Phase I Trial Evaluating Allocetra in Patients with TMJ Osteoarthritis (GlobeNewswire) -6.30%
08:00AM	Loading…
Mar-17-25 08:00AM	Enlivex Receives Notice of Allowance for Chinese Patent Application Covering the Use of Allocetra in Patients with Osteoarthritis (GlobeNewswire) -5.74%
Mar-04-25 04:30PM	Enlivex Therapeutics Announces Investor Webinar to Discuss Positive Interim Data from Phase I/II Allocetra Trial in Knee Osteoarthritis (GlobeNewswire) +5.88%
Mar-03-25 08:22AM	Enlivex Announces Positive Interim Data Statistically Significant 47.0% Durable and Persistent Pain Reduction At Six Months, in Patients with Moderate to Severe Knee Osteoarthritis (GlobeNewswire) -15.00%
Feb-18-25 06:20AM	Enlivex Issues Urgent Statement on Fraudulent News Dissemination (GlobeNewswire)
Feb-11-25 02:30PM	RedChip Announces Webinar to Teach Investors How to Use RedChat, a Revolutionary AI Chatbot for Small-Cap Stock Analysis (ACCESSWIRE)
Jan-10-25 09:00AM	Enlivex Therapeutics and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV (ACCESSWIRE)
Dec-12-24 11:29AM	Enlivex gains Israeli regulatory approval to commence TMJ osteoarthritis trial (Clinical Trials Arena)
Dec-11-24 08:30AM	Enlivex Receives Regulatory Authorization for the Initiation of a Phase I Trial Evaluating Allocetra in Patients with TMJ Osteoarthritis (GlobeNewswire)
Dec-05-24 10:49AM	Enlivex Announces Positive Interim Efficacy Data from Allocetra Trial in Patients with Moderate to Severe Knee Osteoarthritis (GlobeNewswire) -6.15%
Dec-03-24 08:30AM	Enlivex Announces Positive Interim Efficacy Data from Allocetra Trial in Patients with Moderate to Severe Knee Osteoarthritis (GlobeNewswire) +20.37%
Nov-26-24 10:15AM	Join Enlivex Therapeutics' Exclusive Live Investor Webinar and QandA Session on December 3 (ACCESSWIRE)
10:15AM	Join Enlivex Therapeutics' Exclusive Live Investor Webinar and Q&A Session on December 3 (ACCESSWIRE)
Nov-22-24 12:25PM	MicroStrategy Copycats Are Buying Bitcoin as Price Nears $100,000 (Barrons.com) +10.50%
Nov-20-24 08:00AM	Enlivex Adopts Bitcoin Treasury Reserve Strategy (GlobeNewswire) -5.24%
Nov-14-24 08:00AM	Enlivex Announces the Dosing of the First Patient in a Phase I Clinical Trial Evaluating Allocetra in Patients with Psoriatic Arthritis (GlobeNewswire) -8.47%
Nov-12-24 08:00AM	Enlivex Announces the Enrollment and Dosing of the First 10 Patient in the Randomized Phase II Stage of its Allocetra Trial in Patients with Moderate to Severe Knee Osteoarthritis (GlobeNewswire)
Oct-31-24 12:00PM	Enlivex Therapeutics (ENLV) Upgraded to Strong Buy: Here's What You Should Know (Zacks)
Oct-30-24 08:00AM	Enlivex Receives Notice of Allowance for Japanese Patent Application Covering the Use of Allocetra in Patients with Osteoarthritis (GlobeNewswire)
Sep-26-24 08:30AM	Enlivex Receives Authorization from the Danish Medicines Agency to Initiate the Phase II Stage of its Phase I/II Trial of Allocetra in Patients with Moderate to Severe Knee Osteoarthritis (GlobeNewswire) +8.22%
Sep-24-24 08:30AM	Enlivex Announces Positive DSMB Recommendation to Initiate the Phase II Stage of its Phase I/II Trial of Allocetra in Patients with Moderate to Severe Knee Osteoarthritis (GlobeNewswire)
Sep-11-24 12:00PM	All You Need to Know About Enlivex Therapeutics (ENLV) Rating Upgrade to Buy (Zacks)
Aug-30-24 09:00AM	GreenPower and Enlivex Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV (ACCESSWIRE)
Jul-23-24 08:00AM	Enlivex Receives Regulatory Authorization For The Initiation Of A Phase I Clinical Trial To Evaluate Allocetra In Patients With Psoriatic Arthritis (GlobeNewswire) +5.11%
Jul-19-24 09:00AM	Enlivex Therapeutics and Biotricity Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV (ACCESSWIRE)
Jun-24-24 08:00AM	Enlivex Announces the Dosing of the First Patient in a Randomized, Placebo-Controlled Phase I/II Trial Evaluating AllocetraTM in up to 46 Patients with Thumb Osteoarthritis (GlobeNewswire)
Jun-20-24 08:00AM	Join Enlivex Therapeutics' Chief Executive Officer for a Live Investor Webinar and Q&A Session on June 25 (GlobeNewswire)
Jun-17-24 08:00AM	Enlivex Announces Positive Interim Data Readout from a Phase I/II Trial Evaluating Allocetra in End-Stage Knee Osteoarthritis (GlobeNewswire)
Jun-03-24 08:00AM	Enlivex Receives Regulatory Authorization for the Initiation of a Placebo-Controlled Phase I/II Trial Evaluating Allocetra in Up To 46 Patients with Thumb Osteoarthritis (GlobeNewswire) +8.09%
May-29-24 04:15PM	Enlivex Therapeutics Closes up to $15 Million Registered Direct Offering (GlobeNewswire) -5.07%
May-28-24 08:12AM	Enlivex Therapeutics Announces up to $15 Million Registered Direct Offering (GlobeNewswire)
Apr-29-24 08:00AM	Enlivex CEO Issues Letter to Shareholders Perspectives on Recent Events (GlobeNewswire) +15.28%
Apr-22-24 08:00AM	Enlivex Announces Dosing of First Two Patients in its Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Patients with Knee Osteoarthritis (GlobeNewswire)
Apr-16-24 07:50AM	Enlivex Announces Authorization from the Danish Regulatory Agency for the Company's Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Patients with Knee Osteoarthritis (GlobeNewswire) +11.54%
Apr-15-24 01:01PM	Enlivex (ENLV) Stock Plummets 51% in a Week: Here's Why (Zacks) -17.72%
Apr-11-24 02:58PM	Enlivex to Host Webcast on April 12, 2024 at 8:30 a.m. Eastern Time to Discuss Topline Results from Its Phase II Trial Evaluating Allocetra In Patients with Sepsis (GlobeNewswire) -54.02%
08:05AM	Enlivex Announces Topline Results of Its Phase II Trial Evaluating Allocetra In Patients With Sepsis (GlobeNewswire)
Apr-05-24 07:52AM	ENLV Stock Earnings: Enlivex Therapeutics Misses EPS for Q4 2023 (InvestorPlace) +6.38%
Mar-22-24 10:50AM	Enlivex Therapeutics and Unusual Machines Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV (ACCESSWIRE)
Feb-26-24 08:30AM	Enlivex Receives Regulatory Authorization From Israel's Health Ministry For The Initiation Of Phase 1/2 Trial Evaluating Allocetra In Patients With Knee Osteoarthritis (ACCESSWIRE)
Feb-21-24 08:30AM	Enlivex Completes Enrollment Of All 120 Patients In Phase 2 Trial Of Allocetra In Patients With Sepsis, Third-Leading Cause Of Mortality In US Hospitals (ACCESSWIRE)
Feb-07-24 08:00AM	Enlivex Announces Issuance of New U.S. Patent Covering Allocetra Cells and Their Manufacturing Method (GlobeNewswire)
Jan-17-24 08:00AM	Enlivex Receives IMOH Regulatory Authorization for the Initiation of a Multi-Country, Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Up To 160 Patients with Moderate to Severe Knee Osteoarthritis (GlobeNewswire)
Dec-20-23 08:00AM	Enlivex Announces Completion of Enrollment of Its Phase II Trial Evaluating Allocetra In Patients With Sepsis (GlobeNewswire) +22.96%
Nov-21-23 07:00AM	MediWound Announces Appointment of Shmulik Hess, Ph.D. as Chief Operating Officer and Chief Commercial Officer (GlobeNewswire)
Sep-11-23 08:00AM	Enlivex Announces Reprioritization Plan and Second Quarter 2023 Financial Results (GlobeNewswire) -12.73%
Sep-07-23 08:00AM	Enlivex to Present at the H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire)
Aug-02-23 08:00AM	Enlivex Announces Peer-Reviewed Publication in Frontiers in Immunology of Clinical Data Details Resolution of Acute Respiratory Distress Syndrome (ARDS) from two Phase I/II Trials Evaluating Allocetra in Patients with COVID-19 (GlobeNewswire)
Jul-31-23 08:00AM	Enlivex Announces Dosing of First Patient Under The Amended Protocol Of Its Phase II trial Evaluating Allocetra In Patients With Sepsis (GlobeNewswire)
Jun-26-23 08:00AM	Enlivex Announces First Quarter 2023 Financial Results and Provides a Business Update (GlobeNewswire)
Jun-06-23 08:00AM	Enlivex to Present at the 2023 Jefferies Healthcare Conference (GlobeNewswire)
May-31-23 08:04AM	Enlivex Selected for an Elevator Pitch Presentation and two additional Poster Presentations at the 2023 Annual Meeting of the International Society for Cell & Gene Therapy (GlobeNewswire)
May-08-23 08:00AM	Enlivex Announces Issuance of European Patent Covering the Use of Allocetra to Prevent Cytokine Release Syndrome (CRS) Resulting from CAR T-Cell Therapy (GlobeNewswire) +9.12%
Apr-20-23 10:18AM	We Think Enlivex Therapeutics (NASDAQ:ENLV) Needs To Drive Business Growth Carefully (Simply Wall St.)
Apr-19-23 08:00AM	Enlivex Receives Notice of Allowance for U.S. Patent Application Covering the Use of Allocetra in Patients Receiving CAR T-Cell Therapy (GlobeNewswire)
Apr-17-23 08:00AM	Enlivex Appoints Andrew Singer to its Board of Directors (GlobeNewswire)
Apr-14-23 09:40AM	Analysts At H.C. Wainwright & Co. Set 12-Month Target Of $15 Per Share For ENLV Thanks To High Profile Collaboration Agreement, Multiple Ongoing Clinical Trials (ACCESSWIRE)
Apr-12-23 10:45AM	Enlivex, Beigene Collaborate To Test A New Combination Treatment To Fight Advanced-Stage Solid Tumors (ACCESSWIRE)
Apr-10-23 03:07AM	BeiGene, Ltd. (BGNE) Surges 12.5%: Is This an Indication of Further Gains? (Zacks) +6.64%
Apr-04-23 08:00AM	Enlivex Announces Tislelizumab Clinical Collaboration, Full Year 2022 Financial Results, and Provides Business Updates (GlobeNewswire) -32.35%
Apr-03-23 08:00AM	Enlivex Announces Clinical Collaboration to Evaluate Combinations of Allocetra and PD-1 Inhibitor Tislelizumab for Patients with Solid Tumors (GlobeNewswire)
Mar-20-23 08:00AM	Enlivex Receives Positive DSMB Recommendation and IMOH Clearance to Continue Phase I/II Trial of Allocetra combined with chemotherapy in patients with peritoneal metastases arising from solid cancers (GlobeNewswire)
Feb-23-23 08:00AM	Enlivex Receives Clearance From Spanish Agency of Medicines and Medical Devices For Treatment of Patients with Advanced Solid Malignancies in the Ongoing Allocetra Phase I/II Clinical Trial (GlobeNewswire)
Feb-15-23 08:00AM	Enlivex Announces Issuance of Israeli Patent Covering the Use of Allocetra to Prevent Cytokine Release Syndrome (CRS) Resulting from CAR T-Cell Therapy, Infectious Diseases or Any Non-Infectious Source of CRS (GlobeNewswire)
Jan-25-23 08:37AM	Enlivex Announces Positive DSMB Recommendation and IMOH Clearance to Continue Phase I/II Trial of Allocetra in Patients with Advanced Solid Tumors (GlobeNewswire)
Jan-04-23 08:00AM	Enlivex Receives Authorizations from French and Belgian Regulatory Agencies To Expand Its Phase II Sepsis Clinical Trial Into France and Belgium (GlobeNewswire)
Dec-05-22 08:00AM	Enlivex Announces Third Quarter 2022 Financial Results and Provides a Business Update (GlobeNewswire)
Dec-02-22 08:00AM	First Patients Dosed in Phase I/II Trial of Enlivexs Off-the-Shelf Cell Therapy Candidate, AllocetraTM (News Direct)
Dec-01-22 02:00PM	Israeli Ministry Of Health Clears Way For Human Trials Of AllocetraTM, A Proprietary Off-the-Shelf Immunotherapy For Solid Tumors (News Direct)
Nov-28-22 08:00AM	Enlivex Receives Allocetra IND Clearance From The U.S. Food And Drug Administration For Treatment Of Patients with Advanced Solid Malignancies (GlobeNewswire)
Nov-15-22 08:00AM	Enlivex Announces Dosing of the First Patient in Phase I/II Trial Evaluating Allocetra Alone and in Combination with a PD1 Checkpoint Inhibitor in Patients with Advanced Solid Tumors (GlobeNewswire) +6.18%

Enlivex Therapeutics Ltd. engages in the development of macrophage reprogramming immunotherapy products. It focuses on the development of Allocetra, a universal off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. The company was founded by Dror Mevorach on January 22, 2012 and is headquartered in Ness Ziona, Israel.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ENLV

Enlivex Therapeutics Ltd

Upgrade your FINVIZ experience